

European Centre for Disease Prevention and Control

EU/EEA level RSV surveillance data and opportunities

EU/EEA Respiratory Virus Network meeting, session 6

Nick Bundle, ECDC, 14 June 2024

Overview

- Reporting of RSV data to TESSy
- What can we do now with the available data?
- What are we considering to show in future?
- What else could be done?

Reporting of RSV data to TESSy

Week 21, 2023 to week 20, 2024

Data reported 2023-W21 to 2024-W40



Monitoring RSV activity

- 27 countries* reported any activity data activity
- 23 reported non-sentinel, 22 sentinel
 - 6 of these did not report before w40

Monitoring severity of RSV


- 12 countries reported any severity data
- 9 countries reported SARI data
 - 6 of these as case-based SARISURV
- 6 countries reported non-sentinel severity data
 - 3 of these do not have SARI systems
 - 3 of these do have SARI systems, but this non-sentinel data is additional with larger counts of detections

*In practice 25 countries reported sufficient data to be used to track activity – see plot on next slide


What can we do now with the available data?

Historical trends based on multiple countries (ERVISS: since 2015-W40)


Aggregate sentinel tests



Aggregate non-sentinel tests



Sentinel test positivity by country



- Weekly tests up to ~3k sentinel, ~50k non-sentinel in recent years
- Year-round testing reported since 2020 with increasing volume
- Voluntary reporting!

What are we considering to show in future?

For future ERVISS development





1. Enhanced integrated/pathogen-specific display of SARISURV data by age
 - Propose to use the PROMISE recommended age groups (0-2, 3-5, 6-11, 12-23 months, 2-4 years) + finer older age groups
 - Trail this out before any proposals to alter aggregate data age groups
 - Small number of countries submitting data.
 - Restrict to since 2023-W40 due to reporting completeness of AgeMonth variable
2. Display of data by age and RSV type reported to RESPIAGGR

What are we considering to show in future?

Enhanced display of severe disease data by age based on SARISURV

EU/EEA: cumulative tests, detections and positivity by pathogen and age group, 2023-W40 to 2024-W23





What are we considering to show in future?

Enhanced display of severe disease data by age based on SARISURV

EU/EEA: cumulative tests, detections and positivity by pathogen and age group, 2023-W40 to 2024-W23

Pathogen selection

RSV



Consider toggle
for age
proportions or
RSV type



What are we considering to show in future?

Enhanced display of severe disease data by age based on SARISURV

EU/EEA: cumulative tests, detections and positivity by pathogen and age group, 2023-W40 to 2024-W23

Pathogen selection


RSV



What are we considering to show in future?


Enhanced display of severe disease data by age based on SARISURV

EU/EEA: cumulative tests, detections and positivity by pathogen and age group, 2023-W40 to 2024-W23



Pathogen selection

RSV



RSV type only
(incompletely) reported
by 2 countries


What are we considering to show in future?

Display of data by age and RSV type reported to RESPIAGGR

Pathogen selection

RSV

Age-specific RSV sentinel detections by country



Data reported to
RESPIAGGR are age-
disaggregated


What are we considering to show in future?

Display of data by age and RSV type reported to RESPIAGGR

Pathogen selection

RSV

RSV type-specific sentinel detections by country



Data reported to
RESPIAGGR are type-
disaggregated

What else could be done?

If we had increased reporting with high variable completeness


More countries reporting primary care sentinel data to RESPIAGGR:

- Add age and RSV type to regional aggregate plots (incl. age-positivity) as for SARI

More countries reporting to SARISURV:

- More representative of the EU/EEA
- Describe distribution of outcomes, patient risk factors, RSV type, co-infection etc
- Potential for pooled analytical studies, including use of test negative patients

EU/EEA: cumulative detections by pathogen and level of severity, 2023-W40 to 2024-W23



Thank you!